Biotech News

Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer

Lisata Therapeutics (LSTA)Lisata Therapeutics2026-06-25 13:46 ESTCompany update

Stockholders to also receive two contingent value rights valued at $1 per share, each entitled to be received upon the achievement of certain milestones Offer represents an approximate 85% premium over the most recent closing price of Lisata stock BASKING RIDGE, N.J., Jan.

Open original release

Related news

LSTALisata Therapeutics2026-06-25 13:46 EST

Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.

LSTALisata Therapeutics2026-06-25 13:46 EST

Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial

LSTALisata Therapeutics2026-06-25 13:46 EST

Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement

LSTALisata Therapeutics2026-06-25 13:46 EST

Lisata Therapeutics to Present at LD Micro Main Event XIX

LSTALisata Therapeutics2026-06-25 13:46 EST

Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025

LSTALisata Therapeutics2026-06-25 13:46 EST

Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent

LSTALisata Therapeutics2026-06-25 13:46 EST

Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year’

LSTALisata Therapeutics2026-06-25 13:46 EST

Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

LSTALisata Therapeutics2026-06-25 13:46 EST

Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide

LSTALisata Therapeutics2026-06-25 13:46 EST

Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.

View all latest news

Lisata Therapeutics

Lisata Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

LSTALisata Therapeutics2026-06-26 07:29 EST

Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.

LSTALisata Therapeutics2026-06-26 07:29 EST

Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial

LSTALisata Therapeutics2026-06-26 07:29 EST

Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement

LSTALisata Therapeutics2026-06-26 07:29 EST

Lisata Therapeutics to Present at LD Micro Main Event XIX

LSTALisata Therapeutics2026-06-26 07:29 EST

Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States